DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Lilly's Mounjaro"


3 mentions found


☆ Workers are clamoring for pricey new weight-loss drugs like Ozempic. Companies are grappling with how to respond.
  + stars: | 2023-03-06 | by ( ) www.businessinsider.com   time to read: +10 min
Companies that pay for workers' health insurance are grappling with how to cover the pricey drugs. Medicare, the federal program that provides health coverage for people 65 and older, doesn't cover weight-loss drugs. ArcBest already has a program to help workers lose weight through behavior changes and nutrition. Krutsch said he wants to build on that, covering the weight-loss drugs Wegovy and Saxenda for employees who aren't able to lose weight without medication. The new weight-loss drugs were in short supply in 2022, and that gave employers time to figure out how to handle them, he said.
☆ This biotech startup has a chance to grab a piece of the lucrative obesity drug market, analysts say
  + stars: | 2023-02-28 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +3 min
Enter biotech startup Structure Therapeutics , which is hoping to change that regimen with oral GLP-1 formulations for obesity and type 2 diabetes treatment. The stock rallied 73% in its first day of trading, but has pulled back in the weeks since its debut. Novo Nordisk's Wegovy and Ozempic are currently on the market and approved to treat obesity and type 2 diabetes. BMO was among the group of investment banks acting as joint book runners for Structure's IPO. (Jefferies was the lead book runner in Structure's IPO.)
☆ Biotech investor Brad Loncar shares 10 predictions for 2023, including a hot new cancer target, Nobel Prize winners, and a biotech founder running for president
  + stars: | 2023-01-04 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +14 min
Loncar shared his 2023 forecast, including new drugs, Nobel Prize winners, and more globalization. Brad Loncar isn't expecting a miraculous rebound for the biotech industry in 2023. In an interview with Insider, Loncar shared 10 predictions for biotech in 2023, ranging from Nobel Prize winners and presidential runs to hot cancer targets and bankruptcy worries. 2022 was a rough year for the biotech industry, which once again underperformed the stock market. The industry runs to the next super-hot cancer target: Claudin 18.2In cancer research, drug companies are always on the hunt for the next promising target.
<< prev 2 next >>
Total: 3